John C.M. Farquhar Sells 12,837 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 12,837 shares of the stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $22.66, for a total value of $290,886.42. Following the completion of the sale, the chief executive officer owned 581,450 shares in the company, valued at approximately $13,175,657. The trade was a 2.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

John C.M. Farquhar also recently made the following trade(s):

• On Tuesday, February 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $27.46, for a total value of $619,552.52.

Heartflow Price Performance

HTFL opened at $20.49 on Friday. The stock has a market capitalization of $1.74 billion and a price-to-earnings ratio of -11.32. The business has a fifty day moving average price of $27.66 and a 200 day moving average price of $30.69. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $41.22.

Hedge Funds Weigh In On Heartflow

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HTFL. TFC Financial Management Inc. purchased a new position in Heartflow in the third quarter valued at approximately $40,000. Emerald Mutual Fund Advisers Trust acquired a new position in shares of Heartflow in the 3rd quarter valued at $4,418,000. TrueMark Investments LLC acquired a new position in shares of Heartflow in the 3rd quarter valued at $918,000. Baillie Gifford & Co. purchased a new position in shares of Heartflow in the 3rd quarter valued at $101,182,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Heartflow during the 3rd quarter worth $234,000.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of Heartflow in a research note on Wednesday, January 28th. They set an “overweight” rating and a $38.00 target price on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $40.00 price objective on shares of Heartflow in a research report on Monday, March 9th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.